NuCana plc
Close on Oct 19, 2026
About NuCana
Pharmaceutical Preparations, SIC 2834
NuCana plc is a clinical-stage biopharmaceutical company focused on developing therapies for oncology patients. The company utilizes its proprietary ProTide technology to create nucleoside analogs aimed at overcoming cancer drug resistance and enhancing therapeutic efficacy. Its development pipeline includes clinical candidates such as NUC-7738, NUC-3373, and Acelarin, which are evaluated for the treatment of solid tumors and other cancer indications. The company designs its therapeutic candidates to serve cancer patients worldwide.
NuCana is incorporated in England and Wales and conducts its principal operations from its executive headquarters in Edinburgh, United Kingdom. As a development-stage biopharmaceutical organization, it oversees clinical research and development activities across multiple international jurisdictions. Administrative functions, research management, and corporate operations are directed from its facility located in the United Kingdom.
Summary of the business section of NuCana's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NuCana plc
- Headquarters
- Edinburgh, X0
- Address
- 3 Lochside Way EH12 9DT
- Phone
- 44-0-131-357-1111
- Website
- nucana.com
- Employees
- 12, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- X0
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Edinburgh, United Kingdom
Stock & identifiers
- Ticker
- NCNA
- Exchange
- Nasdaq
- IPO date
- Sep 29, 2017
- Shares outstanding
- 20.81B, Dec 31, 2025
- Filer category
- Non-accelerated filer
- Stock splits
- 1-for-200 reverse, Aug 11, 2025; 1-for-25 reverse, Apr 16, 2024
- SEC CIK
- 1709626
- CUSIP
- 67022C304
- ISIN
- US67022C3043
- LEI
- 213800K5NF92PPHPA304
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Hugh Griffith | Chief Executive Officer, Director | 1,000,000 |
| Jeffrey D. Bloss | Chief Medical Officer | 47,136 |
| Theresa Margaret Ms Bruce | Chief Operating Officer | – |
| David James Harrison | Head of Translational Medicine | – |
| Ian Alexander Webster | See Remarks | – |
| Elliott M. Levy | Director | 13 |
| Martin C.B. Mellish | Director | 28 |
| Cyrille Leperlier | Director | – |
| Andrew Martin Kay | Director | – |
Employees
Headcount reported in annual reports
“We are a clinical development-stage company, and, as of December 31, 2025, had 12 employees, including four executive officers.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 29, 2017 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 22, 2017 | Listing | Registration of securities on an exchange (Form 8-A) |
| Aug 4, 2017 | Name change | Name changed from NuCana BioMed Ltd to NuCana plc |